Neuropathic Pain Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Neuropathic Pain Market is segmented by Indication (Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-induced Peripheral Neuropathy), Drug Class, Distribution Channel and Geography

Neuropathic Pain Market Snapshot

Neuropathic Pain Market
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 5.4 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Neuropathic Pain market studied is anticipated to grow with a CAGR of nearly 5.4%, during the forecast period. Certain factors that are driving the market growth includes the rising prevalence of diabetic neuropathy and other targeted diseases and increasing healthcare expenditure and research funding. As per the 2018 report published by Kelsey Juster-Switlyk et al, Diabetes has become one of the largest global health-care problems. The number of people with diabetes worldwide is projected to double between 2000 and 2030, reaching a pandemic level of 366 million people. 

Diabetic polyneuropathy (DPN) has a lifetime prevalence of nearly 50%, and it is the most common diabetic complication. DPN is a prominent cause for disability due to foot ulceration and amputation, gait disturbance, and fall-related injury. Around 20 to 30% of patients with DPN suffer from neuropathic pain. DPN significantly lowers the quality of life and substantially increases the health costs associated with diabetes. The total annual medical costs for diabetes is USD 6,632 per patient. People suffering from DPN experience a twofold increase in health-care costs (USD 12,492), and those with severe painful peripheral neuropathy experience a fourfold increase (USD 30,755).

All these afore-mentioned factors are boosting the growth in demand for effective medication in order to treat and cure neuropathic pain.

Scope of the Report

As per the scope, neuropathic pain refers to the pain caused by damage or disease affecting the somatosensory nervous system. The disease is relatively common but often poorly treated. The market studied is segmented on the basis of indication, drug class, distribution channel and geography.

By Indication
Diabetic Neuropathy
Spinal Stenosis
Chemotherapy-induced Peripheral Neuropathy
By Drug Class
Tricyclic Antidepressants
Capsaicin Cream
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Opioid Holds Significant Share in the Neuropathic Pain Market

Opioids are considered as some of the most effective drugs for management of pain. Moreover, their use in the management of severe pain and chronic pain, which are associated with advanced medical illness, is considered to be standard practice in most parts of the world. An agonist is a drug that triggers certain receptors in the brain. Methadone (strong) agonist therapy is an effective treatment for addiction to opioid drugs (such as heroin). Strong agonist opioids activate opioid receptors, and after binding tightly, undergo significant conformational changes. Strong agonists include codeine, fentanyl, heroin, hydrocodone, methadone, morphine, and oxycodone.

As per the US Department of Health and Human Services and National Institutes of Health, in 2015, 25.4 million Americans adults experienced pain daily. These statistics indicates the importance of pain management and impacts the opioid segment positively.

Neuropathic Pain Market 1

North America Dominates the Global Neuropathic Pain Market

  • In the North American region, the United States has been accounted for the largest market share. The presence of major market players and huge pharmaceutical and biopharmaceutical industries, coupled with the rising investments in the country for the adoption of advanced technologies, is expected to boost the regional growth of the market over the forecast period.
  • In addition, the rising concern about the prevalence of neuropathy and other associated disorders is stimulating the need for the adoption of neuropathic pain medications.
  • Asia-Pacific, on the other hand, is expected to grow with the fastest growth rate over the forecast period.
Neuropathic Pain Market 2

Competitive Landscape

The global Neuropathic Pain market is competitive and consists of a few major players. Companies like Grünenthal, Mallinckrodt Pharmaceuticals, AstraZeneca, Biogen Inc., Eli Lilly and Company, GlaxoSmithKline Plc, Johnson & Johnson, Pfizer, Inc., Sanofi, among others, hold the substantial market share in the market.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Prevalence of Diabetic Neuropathy and Other Targetted Diseases

      2. 4.2.2 Increasing Healthcare Expenditure and Research Funding

    3. 4.3 Market Restraints

      1. 4.3.1 Side Effects of Treatments and Availability of Counterfeit Drugs

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Indication

      1. 5.1.1 Diabetic Neuropathy

      2. 5.1.2 Spinal Stenosis

      3. 5.1.3 Chemotherapy-induced Peripheral Neuropathy

      4. 5.1.4 Others

    2. 5.2 By Drug Class

      1. 5.2.1 Tricyclic Antidepressants

      2. 5.2.2 Opioids

      3. 5.2.3 Capsaicin Cream

      4. 5.2.4 Steroids

      5. 5.2.5 Others

    3. 5.3 By Distribution Channel

      1. 5.3.1 Hospital Pharmacies

      2. 5.3.2 Retail Pharmacies

      3. 5.3.3 Others

    4. 5.4 Geography

      1. 5.4.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.4.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Grünenthal

      2. 6.1.2 Mallinckrodt Pharmaceuticals

      3. 6.1.3 AstraZeneca

      4. 6.1.4 Biogen Inc.

      5. 6.1.5 Eli Lilly and Company

      6. 6.1.6 GlaxoSmithKline Plc

      7. 6.1.7 Johnson & Johnson

      8. 6.1.8 Pfizer, Inc.

      9. 6.1.9 Sanofi

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Neuropathic Pain Market market is studied from 2018 - 2026.

The Neuropathic Pain Market is growing at a CAGR of 5.4% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Eli Lilly and Company, Grünenthal, Biogen Inc., Pfizer, Inc., Mallinckrodt Pharmaceuticals are the major companies operating in Neuropathic Pain Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!